SCHEDULE 13G/A: Perceptive Advisors Reduces Stake in Spyre Therapeutics to 4.4%
Beneficial Ownership Report
Perceptive Advisors LLC and its affiliates have reduced their beneficial ownership in Spyre Therapeutics, Inc. to 4.4% of the common stock, as disclosed in a recent SEC Schedule 13G/A filing.
Summary
- Perceptive Advisors LLC, Joseph Edelman, and Perceptive Life Sciences Master Fund, Ltd. (collectively, the "Reporting Persons") have filed an Amendment No. 3 to Schedule 13G regarding their beneficial ownership in Spyre Therapeutics, Inc.
- As of December 31, 2024, the Reporting Persons collectively beneficially own 2,574,723 shares of Spyre Therapeutics, Inc. Common Stock.
- This ownership represents 4.4% of the Issuer's outstanding Common Stock.
- The percentage is calculated based on 58,670,608 shares of Common Stock outstanding as of November 20, 2024, as reported by the Issuer.
- Perceptive Life Sciences Master Fund, Ltd. directly holds all 2,574,723 shares.
- Perceptive Advisors LLC serves as the investment manager to the Master Fund, and Joseph Edelman is the managing member of Perceptive Advisors LLC, granting them shared voting and dispositive power over the shares.
Sentiment
Score: 4
Explanation: The sentiment is slightly negative due to the reduction in beneficial ownership by a significant institutional investor, suggesting a partial divestment.
Positives
- The continued presence of a prominent life sciences investor like Perceptive Advisors on the shareholder register, even with a reduced stake, may still signal some level of confidence in Spyre Therapeutics' long-term prospects.
Negatives
- The reduction in beneficial ownership from a previous stake (implied to be 5% or more, given the 'Amendment No. 3' and current 4.4% holding) indicates a partial divestment by a significant institutional investor.
Future Outlook
This Schedule 13G/A filing is a disclosure of current beneficial ownership and does not contain any forward-looking statements or guidance regarding Spyre Therapeutics, Inc.'s future performance or strategic direction.
Industry Context
This filing represents a routine disclosure of institutional ownership in a publicly traded biotechnology or pharmaceutical company. The reduction in stake by a specialized life sciences investor like Perceptive Advisors could be observed by other market participants as they assess investment trends within the sector.
Stakeholder Impact
- Shareholders: Provides transparency regarding significant institutional ownership changes, which may influence investor sentiment and trading decisions.
- Investment Professionals: Offers insight into the portfolio adjustments of a notable life sciences fund, potentially informing their own investment strategies.
Key Dates
| Date | Description |
|---|---|
| 2024-11-20 | Date as of which 58,670,608 shares of Common Stock were reported outstanding by the Issuer. |
| 2024-12-31 | Date of event which requires filing of this statement (reporting period end date). |
| 2025-02-14 | Date of filing and signature date for the Schedule 13G/A. |
Keywords
Spyre Therapeutics, Perceptive Advisors, Joseph Edelman, Perceptive Life Sciences Master Fund, SEC filing, Schedule 13G, beneficial ownership, common stock, institutional investor, equity stake
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.